Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 46

1.

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.

Heigener DF, Deppermann KM, Pawel JV, Fischer JR, Kortsik C, Bohnet S, Eiff MV, Koester W, Thomas M, Schnabel PA, Reck M.

Lung Cancer. 2014 Apr;84(1):62-6. doi: 10.1016/j.lungcan.2014.01.024. Epub 2014 Feb 3.

PMID:
24560332
[PubMed - in process]
2.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team.

Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.

PMID:
24331154
[PubMed - indexed for MEDLINE]
3.

The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).

Gottschling S, Herpel E, Eberhardt WE, Heigener DF, Fischer JR, Köhne CH, Kortsik C, Kuhnt T, Muley T, Meister M, Bischoff HG, Klein P, Moldenhauer I, Schnabel PA, Thomas M, Penzel R.

Lung Cancer. 2012 Jul;77(1):183-91. doi: 10.1016/j.lungcan.2012.03.003. Epub 2012 Apr 7.

PMID:
22483783
[PubMed - indexed for MEDLINE]
4.

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.

O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, von Pawel J, Ramlau R, Roh JK, Yu CT, Stroh C, Celik I, Schueler A, Pirker R.

Lancet Oncol. 2011 Aug;12(8):795-805. doi: 10.1016/S1470-2045(11)70189-9. Epub 2011 Jul 22.

PMID:
21782507
[PubMed - indexed for MEDLINE]
5.

The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.

Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, Fritsch H, Gaschler-Markefski B, Hanft G, Munzert G, von Pawel J.

J Thorac Oncol. 2010 Jul;5(7):1060-7. doi: 10.1097/JTO.0b013e3181d95dd4.

PMID:
20526206
[PubMed - indexed for MEDLINE]
6.

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team.

Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.

PMID:
19410716
[PubMed - indexed for MEDLINE]
7.

MHC class II tetramer guided detection of Mycobacterium tuberculosis-specific CD4+ T cells in peripheral blood from patients with pulmonary tuberculosis.

Höhn H, Kortsik C, Zehbe I, Hitzler WE, Kayser K, Freitag K, Neukirch C, Andersen P, Doherty TM, Maeurer M.

Scand J Immunol. 2007 May;65(5):467-78.

PMID:
17444958
[PubMed - indexed for MEDLINE]
8.

A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).

Laack E, Thöm I, Krüll A, Engel-Riedel W, Müller T, Meissner C, Dürk H, Fischer J, Gütz S, Kortsik C, Elbers M, Schuch G, Andritzky B, Görn M, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C.

Lung Cancer. 2007 Aug;57(2):181-6. Epub 2007 Apr 17.

PMID:
17442447
[PubMed - indexed for MEDLINE]
9.

Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis.

Weichold FF, Mueller S, Kortsik C, Hitzler WE, Wulf MJ, Hone DM, Sadoff JC, Maeurer MJ.

Genes Immun. 2007 Jun;8(4):334-43. Epub 2007 Apr 12.

PMID:
17429413
[PubMed - indexed for MEDLINE]
10.

Dysfunctional inhibitory muscarinic receptors mediate enhanced histamine release in isolated human bronchi.

Wessler I, Hölper B, Kortsik C, Buhl R, Kilbinger H, Kirkpatrick CJ.

Life Sci. 2007 May 30;80(24-25):2294-7. Epub 2007 Jan 23.

PMID:
17320912
[PubMed - indexed for MEDLINE]
11.

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.

Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ.

Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11.

PMID:
15824080
[PubMed - indexed for MEDLINE]
Free Article
12.

Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.

Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):690-6.

PMID:
15701857
[PubMed - indexed for MEDLINE]
Free Article
13.

Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection.

Tully G, Kortsik C, Höhn H, Zehbe I, Hitzler WE, Neukirch C, Freitag K, Kayser K, Maeurer MJ.

J Immunol. 2005 Feb 15;174(4):2174-84.

PMID:
15699149
[PubMed - indexed for MEDLINE]
Free Article
14.

Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.

Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group.

J Clin Oncol. 2004 Jun 15;22(12):2348-56.

PMID:
15197195
[PubMed - indexed for MEDLINE]
Free Article
15.

Expression of KIT (CD117) in biphasic pulmonary blastoma. Novel data on histogenesis.

Hansen T, Bittinger F, Kortsik C, Wagner B, Kirkpatrick CJ.

Lung. 2003;181(4):193-200.

PMID:
14692559
[PubMed - indexed for MEDLINE]
16.

Longitudinal analysis of Mycobacterium tuberculosis 19-kDa antigen-specific T cells in patients with pulmonary tuberculosis: association with disease activity and cross-reactivity to a peptide from HIVenv gp120.

Höhn H, Kortsik C, Tully G, Nilges K, Necker A, Freitag K, Neukirch C, Galle P, Löhr H, Maeurer MJ.

Eur J Immunol. 2003 Jun;33(6):1613-23.

PMID:
12778479
[PubMed - indexed for MEDLINE]
17.

Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study.

Kortsik C, Albrecht P, Elmer A.

Lung Cancer. 2003 Apr;40(1):85-90.

PMID:
12660012
[PubMed - indexed for MEDLINE]
18.

Pleural effusion due to Histoplasma capsulatum and idiopathic CD4 lymphocytopenia.

Kortsik C, Elmer A, Tamm I.

Respiration. 2003 Jan-Feb;70(1):118-22.

PMID:
12584405
[PubMed - indexed for MEDLINE]
Free Article
19.

Definition of the HLA-A2 restricted peptides recognized by human CD8+ effector T cells by flow-assisted sorting of the CD8+ CD45RA+ CD28- T cell subpopulation.

Höhn H, Jülch M, Pilch H, Kortsik C, Tully G, Neukirch C, Freitag K, Maeurer M.

Clin Exp Immunol. 2003 Jan;131(1):102-10.

PMID:
12519392
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Human leucocyte antigen-A2 restricted and Mycobacterium tuberculosis 19-kDa antigen-specific CD8+ T-cell responses are oligoclonal and exhibit a T-cell cytotoxic type 2 response cytokine-secretion pattern.

Höhn H, Kortsik C, Nilges K, Necker A, Freitag K, Tully G, Neukirch C, Maeurer MJ.

Immunology. 2001 Nov;104(3):278-88.

PMID:
11722642
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk